Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression

Experimental and Therapeutic Medicine

Volumn 6, Issue 4, 2013, Pages 929-936

  Zheng, Zhen ^a   Li, Xu ^a   Li, Zhiliang ^a   Ma, Xiaochun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic failure; Liver support systems; Meta analysis

Indexed keywords

BILIRUBIN;

ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ARTICLE; BIOARTIFICIAL LIVER; BLEEDING; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; LIVER SUPPORT; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS;

EID: 84883234258     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1241     Document Type: Article

References (40)

1. Tuñón MJ, Alvarez M, Culebras JM and González-Gallego J: An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World J Gastroenterol 15: 3086-3098, 2009.
2. Stadlbauer V, Krisper P, Aigner R, et al: Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 10: R169, 2006.
3. Bernal W, Auzinger G, Dhawan A and Wendon J: Acute liver failure. Lancet 376: 190-201, 2010.
4. van de Kerkhove MP, Hoekstra R, Chamuleau RA and van Gulik TM: Clinical application of bioartificial liver support systems. Ann Surg 240: 216-230, 2004.
5. Carpentier B, Gautier A and Legallais C: Artificial and bioartificial liver devices: present and future. Gut 58: 1690-1702, 2009.
6. Wang Y, Susando T, Lei X, et al: Current development of bioreactors for extracorporeal bioartificial liver (Review). Biointerphases 5: FA116-FA131, 2010.
7. Pless G: Bioartificial liver support systems. Methods Mol Biol 640: 511-523, 2010.
8. Millis JM and Losanoff JE: Technology insight: liver support systems. Nat Clin Pract Gastroenterol Hepatol 2: 398-405. quiz 434, 2005.
9. Nevens F and Laleman W: Artificial liver support devices as treatment option for liver failure. Best Pract Res Clin Gastroenterol 26: 17-26, 2012.
10. Schilsky ML: Acute liver failure and liver assist devices. Transplant Proc 43: 879-883, 2011.
11. Liu JP, Gluud LL, Als-Nielsen B and Gluud C: Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev CD003628, 2004.
12. Kjaergard LL, Liu J, Als-Nielsen B and Gluud C: Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 289: 217-222, 2003.
13. Stutchfield BM, Simpson K and Wigmore SJ: Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg 98: 623-631, 2011.
14. Knobloch K, Yoon U and Vogt PM: Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 39: 91-92, 2011.
15. Moher D, Schulz KF and Altman DG; CONSORT GROUP (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134: 657-662, 2001.
16. Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558, 2002.
17. Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137, 2005.
18. Ioannidis JP, Patsopoulos NA and Rothstein HR: Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 336: 1413-1415, 2008.
19. Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680, 2006.
20. Redeker AG and Yamahiro HS: Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet 1: 3-6, 1973.
21. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD and Williams R: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94: 1186-1192, 1988.
22. Davenport A, Will EJ and Davison AM: Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 41: S245-S251, 1993.
23. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA and Williams R: Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 17: 657-662, 1994.
24. Ellis AJ, Hughes RD, Wendon JA, et al: Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 24: 1446-1451, 1996.
25. Mazariegos GV, Linden F, Kramer D, Patzer J and Fung JJ: Randomized clinical trial of the BioLogic-DT in treatment of acute hepatic failure (AHF) with advanced encephalopathy. Hepatology 26 (Suppl): 559A, 1997.
26. Kramer L, Gendo A, Madl C, Mullen K, Kaminski-Russ K and Zauner C: A controlled study of the BioLogic-DT System in chronic hepatic encephalopathy. Hepatology 28 (Suppl): 401A, 1998.
27. Wilkinson AH, Ash SR and Nissenson AR: Hemodiabsorption in treatment of hepatic failure. J Transpl Coord 8: 43-50, 1998.
28. Ellis AJ, Hughes RD, Nicholl D, et al: Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Int J Artif Organs 22: 27-34, 1999.
29. He JQ, Chen CY, Deng JT, Qi HX, Zhang XQ and Chen ZQ: Clinical study on the treatment of fatal hepatitis with artificial liver support system. Chinese Critical Care Medicine 12(2): 105-108, 2000 (In Chinese).
30. Mitzner SR, Stange J, Klammt S, et al: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277-286, 2000.
31. Stevens AC, Busuttil R, Hans S, et al: An interim analysis of a phase prospective randomized, multicenter, controlled trial of the HepatAssist® bioartificial liver support system for the treatment of fulminant hepatic failure. Hepatology 34 (Suppl): 299A, 2001.
32. Heemann U, Treichel U, Loock J, et al: Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36: 949-958, 2002.
33. Demetriou AA, Brown RS Jr, Busuttil RW, et al: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 239: 660-670, 2004.
34. El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D and Koerfer R: First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 50: 332-337, 2004.
35. Sen S, Davies NA, Mookerjee RP, et al: Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 10: 1109-1119, 2004.
36. Laleman W, Wilmer A, Evenepoel P, et al: Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 10: R108, 2006.
37. Hassanein TI, Tofteng F, Brown RS Jr, et al: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46: 1853-1862, 2007.
38. Kribben A, Gerken G, Haag S, et al: Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 142: 782-789, 2012.
39. Allen JW, Hassanein T and Bhatia SN: Advances in bioartificial liver devices. Hepatology 34: 447-455, 2001.
40. Sorkine P, Ben Abraham R, Szold O, et al: Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 29: 1332-1336, 2001.